Design, Synthesis of Novel Quinazolinone Derivatives and Evaluation of EGFR Kinase Inhibition Activity via In Vitro and In Silico Studies
Chemical Biology & Drug Design · 2026
DOI: 10.1111/cbdd.70338 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2026. Verfasst von Aybüke Züleyha Kaya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Anadolu University, Eskisehir, Turkey. Hauptthemen laut MEDLINE: Quinazolinones, Protein Kinase Inhibitors, Drug Design, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anadolu Üniversitesi.
Abstract (Originalsprache)
Cancer is one of the most seen diseases worldwide. Due to the serious side effects of anticancer drugs and toxic effects on healthy cells, investigations for novel anticancer agents with low side effects have become one of the most important research areas of our age. With this objective, 17 new compounds were designed and successfully synthesized based on the quinazolinone, which is commonly found in the structures of FDA‐approved EGFR inhibitors, and their structures were elucidated by IR, HRMS, 1 H, and 13 C‐NMR spectral analysis methods. According to cytotoxicity test results, it was determined that compound 4j showed high inhibitory activity compared to cisplatin and gefitinib in the A549 cell line. In apoptosis induction studies, it was observed that compounds 4a , 4b , 4d , and 4f showed activity in the A549 cell line, while compound 4j showed activity in the MCF‐7 cell line. In the study investigating caspase‐3 activation, compounds 4a , 4m , and 4o were found active in the A549 cell line, while compounds 4a and 4o were found active in MCF‐7 cells. In EGFR enzyme inhibition studies, it was observed that the activities of molecules 4b , 4f , and 4j were higher than gefitinib. In silico studies indicated that 4j interacted by establishing significant bonds with both caspase‐3 and EGFR enzyme.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Anadolu University, Eskisehir, Turkey.
- Institute of Graduate Education, Anadolu University, Eskisehir, Turkey.
- Faculty of Pharmacy, Department of Biochemistry, Anadolu University, Eskisehir, Turkey.
ORCID-Profile: Aybüke Züleyha Kaya, Asaf Evrim Evren, Gülşen Akalın-Çiftçi, Leyla Yurttaş
Förderung
- Anadolu Üniversitesi
Zitieren
APA
Kaya, A. Z., Evren, A. E., Akalın-Çiftçi, G., & Yurttaş, L. (2026). Design, Synthesis of Novel Quinazolinone Derivatives and Evaluation of EGFR Kinase Inhibition Activity via In Vitro and In Silico Studies. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70338
Vancouver
Kaya AZ, Evren AE, Akalın-Çiftçi G, Yurttaş L. Design, Synthesis of Novel Quinazolinone Derivatives and Evaluation of EGFR Kinase Inhibition Activity via In Vitro and In Silico Studies. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70338
BibTeX
@article{Kaya2026,
author = {Kaya, Aybüke Züleyha and Evren, Asaf Evrim and Akalın-Çiftçi, Gülşen and Yurttaş, Leyla},
title = {Design, Synthesis of Novel Quinazolinone Derivatives and Evaluation of EGFR Kinase Inhibition Activity via In Vitro and In Silico Studies},
journal = {Chemical Biology & Drug Design},
year = {2026},
doi = {10.1111/cbdd.70338}
}
EUVIMED